Pfizer Inc. (NYSE:PFE) Holdings Lowered by Stokes Family Office LLC

Stokes Family Office LLC lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.7% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 73,225 shares of the biopharmaceutical company’s stock after selling 2,033 shares during the period. Stokes Family Office LLC’s holdings in Pfizer were worth $2,032,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of PFE. Clifford Swan Investment Counsel LLC boosted its holdings in shares of Pfizer by 4.7% in the fourth quarter. Clifford Swan Investment Counsel LLC now owns 417,070 shares of the biopharmaceutical company’s stock worth $12,007,000 after buying an additional 18,611 shares during the period. LifePlan Financial LLC acquired a new position in shares of Pfizer in the fourth quarter worth about $255,000. Cantor Fitzgerald Investment Advisors L.P. acquired a new position in shares of Pfizer in the fourth quarter worth about $16,166,000. KLCM Advisors Inc. boosted its holdings in shares of Pfizer by 75.0% in the fourth quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock worth $5,004,000 after buying an additional 74,487 shares during the period. Finally, Farmers Trust Co. boosted its holdings in shares of Pfizer by 2.0% in the fourth quarter. Farmers Trust Co. now owns 225,881 shares of the biopharmaceutical company’s stock worth $6,503,000 after buying an additional 4,410 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Performance

PFE stock traded up $0.26 on Friday, reaching $28.92. 28,153,470 shares of the company were exchanged, compared to its average volume of 40,011,234. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $37.80. The stock’s fifty day moving average price is $28.23 and its 200 day moving average price is $27.72. The firm has a market capitalization of $163.88 billion, a PE ratio of -484.33, a PEG ratio of 1.11 and a beta of 0.69. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78.

Pfizer (NYSE:PFE) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. During the same quarter in the previous year, the firm posted $1.23 earnings per share. Pfizer’s revenue was down 19.5% compared to the same quarter last year. On average, research analysts anticipate that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be paid a dividend of $0.42 per share. The ex-dividend date is Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a yield of 5.81%. Pfizer’s dividend payout ratio is currently -2,800.00%.

Analyst Ratings Changes

PFE has been the subject of several research reports. Barclays raised their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Morgan Stanley lifted their target price on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. BMO Capital Markets reiterated an “outperform” rating and issued a $36.00 target price (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Wednesday. Nine research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $35.69.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.